Summary

The global biopharmaceutical market size reached US$ 300.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 643.9 Billion by 2032, exhibiting a growth rate (CAGR) of 8.6% during 2024-2032. The escalating demand for personalized medicines, the growing prevalence of chronic and lifestyle-related diseases, and rapid advancements in biotechnology, including genetic engineering and recombinant DNA technology, are among the key factors driving the market growth.

Biopharmaceuticals, also known as biologics, are a class of pharmaceutical drugs derived from biological sources. They are produced using living organisms, such as bacteria, yeast, or mammalian cells, through biotechnological processes. Unlike traditional small-molecule drugs, which are chemically synthesized, biopharmaceuticals are large, complex molecules that exhibit highly specific interactions with biological targets in the body. They offer several advantages over traditional pharmaceuticals. They tend to be highly specific in their action, often targeting specific receptors or molecules, resulting in increased efficacy and reduced side effects. Additionally, biopharmaceuticals have the potential to treat diseases that were previously challenging to address using conventional drugs.

The market is experiencing significant growth due to the escalating demand for personalized medicine. In addition, the increasing utilization of biopharmaceuticals to treat cancer, diabetes, psoriasis, and rheumatoid arthritis represents another major growth-inducing factor. Besides, the growing awareness among the masses regarding the effectiveness and availability of biopharmaceuticals represents another major growth-inducing factor. Moreover, the rising focus on rare diseases and orphan drugs is driving the growth of the market. These rare diseases, often characterized by small patient populations, present significant unmet medical needs. Other than this, governments and regulatory agencies worldwide have introduced incentives and streamlined regulatory processes to encourage the development of therapies for these conditions. Moreover, biopharmaceutical companies are investing in R&D to develop orphan drugs, which target rare diseases, thereby addressing critical medical needs and creating opportunities for market expansion.

Biopharmaceutical Market Trends/Drivers:
The escalating demand for personalized medicine

Personalized medicine has led to a shift toward targeted therapies and precision medicine approaches in the biopharmaceutical market. Biopharmaceutical companies are increasingly focusing on the development of therapies that target specific genetic mutations, biomarkers, or molecular pathways associated with diseases. Moreover, personalized medicine has led to advancements in pharmacogenomics, which is the study of how an individual's genetic makeup influences their response to drugs. Understanding the genetic variations that impact drug metabolism, efficacy, and safety allows for the identification of patients who may be at risk of adverse reactions or those who are more likely to respond favorably to a specific treatment. This knowledge enables biopharmaceutical companies to develop targeted therapies and dosage regimens tailored to individual patients, enhancing treatment effectiveness and reducing the risk of adverse events.

The growing prevalence of chronic and lifestyle-related diseases

Chronic diseases, including cardiovascular disorders, diabetes, cancer, respiratory diseases, and autoimmune conditions, have become major global health challenges. These diseases often have complex underlying mechanisms, requiring targeted and personalized treatment approaches. Biopharmaceuticals, such as monoclonal antibodies, recombinant proteins, and gene therapies, offer precise targeting and tailored treatment options. These therapies can target specific molecular pathways, receptors, or cells associated with chronic diseases, resulting in enhanced efficacy and reduced side effects. Moreover, the increasing burden of chronic and lifestyle-related diseases has shifted the focus from symptomatic relief to disease modification and prevention, which is also propelling the market growth.

Various advancements in biotechnology

Biotechnology has greatly accelerated the drug discovery and development process. Advanced techniques, such as high-throughput screening, combinatorial chemistry, and computational modeling, enable the identification and testing of a large number of drug candidates in a shorter time frame. This has led to an increase in the efficiency and speed of drug discovery, allowing biopharmaceutical companies to bring new therapies to market more rapidly. Besides, the ability to analyze an individual's genetic makeup, identify disease markers, and understand molecular pathways has enabled the development of targeted therapies tailored to specific patient populations. Biotechnology tools, such as genomics, next-generation sequencing, and gene editing techniques, have revolutionized the understanding of disease mechanisms and enabled the development of therapies that address specific genetic variations and molecular targets, thus propelling the market.

Biopharmaceutical Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global biopharmaceutical market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on indication and class.

Breakup by Indication:
Autoimmune Diseases
Oncology
Metabolic Disorders
Others

Autoimmune diseases represent the leading segment

The report has provided a detailed breakup and analysis of the market based on the indication. This includes autoimmune diseases, oncology, metabolic disorders, and others. According to the report, autoimmune diseases represented the largest segment.

Autoimmune diseases are often chronic and complex conditions that require long-term management and treatment. These diseases can affect multiple organs and systems in the body, leading to a wide range of symptoms and complications. Biopharmaceutical therapies have shown promising results in managing and controlling autoimmune diseases, providing relief from symptoms, slowing disease progression, and improving quality of life for patients. Therapies, including monoclonal antibodies and other biologics, have emerged as a vital treatment option for autoimmune diseases. They target specific molecules, cells, or pathways involved in the autoimmune response, providing more precise and effective therapeutic interventions.

Breakup by Class:

Recombinant Proteins
Monoclonal Antibodies
Purified Proteins

Monoclonal antibodies exhibit a clear dominance in the market

A detailed breakup and analysis of the market based on the class has also been provided in the report. This includes recombinant proteins, monoclonal antibodies, and purified proteins. According to the report, monoclonal antibodies accounted for the largest market share.

Monoclonal antibodies are highly specific in targeting disease-specific antigens or cells. They are designed to bind to a specific target with precision, minimizing off-target effects and reducing the risk of adverse reactions. This specificity contributes to their efficacy in treating various diseases, including autoimmune disorders, cancer, inflammatory conditions, and infectious diseases. They also have a wide range of therapeutic applications across different disease areas. They can be used as therapeutic agents on their own or in combination with other treatments. Monoclonal antibodies have been successful in neutralizing pathogens, blocking cell receptors, modulating immune responses, and delivering therapeutic payloads, making them versatile tools for disease management.

Breakup by Region:

North America
United States
Canada
Latin America
Mexico
Brazil
Argentina
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Turkey
Asia Pacific
Japan
China
Australia
South Korea
India
Indonesia

North America accounts for the majority of market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Latin America (Mexico, Brazil, and Argentina); Europe (Germany, France, Italy, Spain, the United Kingdom, Russia, and Turkey); and Asia Pacific (Japan, China, Australia, South Korea, India, and Indonesia). According to the report, North America was the largest market for biopharmaceuticals.

North America, particularly the United States, boasts a highly developed healthcare infrastructure, including robust research and development capabilities, advanced clinical facilities, and a strong regulatory framework. The region is home to renowned academic institutions, pharmaceutical companies, and research organizations that drive innovation in the biopharmaceutical industry. The presence of these institutions and infrastructure facilitates the development, manufacturing, and commercialization of biopharmaceutical products. The region has a well-established ecosystem that supports biopharmaceutical innovation, including government funding initiatives, research grants, venture capital investments, and collaborations between academia, industry, and research institutes.

Competitive Landscape:
The competitive landscape of the biopharmaceutical market is highly dynamic and competitive, with numerous global and regional players vying for market share. Nowadays, leading biopharmaceutical companies are heavily investing in R&D to discover and develop innovative therapies. They are conducting preclinical and clinical trials, and advance promising candidates through the regulatory approval process. These investments aim to expand their product pipelines, address unmet medical needs, and stay ahead of competitors in terms of therapeutic advancements. They are also forming strategic partnerships and collaborations with academic institutions, research organizations, and other industry players. These alliances enable them to access new technologies, scientific expertise, and complementary resources.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.
Amgen Inc
Biogen Inc.
Eli Lilly and Company
F. Hoffmann-La Roche AG
Johnson & Johnson
Merck & Co. Inc.
Novo Nordisk A/S
Pfizer Inc.
Sanofi S.A

Recent Developments:
Pfizer and BioNTech developed and distributed their mRNA-based COVID-19 vaccine, Comirnaty (BNT162b2). The vaccine received emergency use authorizations and has been widely deployed globally, playing a crucial role in combating the COVID-19 pandemic.
Amgen Inc. recently received FDA approval for Lumakras (sotorasib), a targeted therapy for non-small cell lung cancer (NSCLC) with specific genetic mutations.
AbbVie Inc. has made significant advancements in immunology, particularly with its flagship product, Humira (adalimumab). Humira is one of the world's best-selling biologic drugs used to treat autoimmune conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease.

Key Questions Answered in This Report

1. What was the size of the global biopharmaceutical market in 2023?
2. What is the expected growth rate of the global biopharmaceutical market during 2024-2032?
3. What are the key factors driving the global biopharmaceutical market?
4. What has been the impact of COVID-19 on the global biopharmaceutical market?
5. What is the breakup of the global biopharmaceutical market based on the indication?
6. What is the breakup of the global biopharmaceutical market based on the class?
7. What are the key regions in the global biopharmaceutical market?
8. Who are the key players/companies in the global biopharmaceutical market?

ページTOPに戻る

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
5 Global Biopharmaceutical Market
5.1 Market Performance and Forecast
5.1.1 Current Performance (2018-2023)
5.1.2 Market Forecast (2024-2032)
5.2 Impact of COVID-19
5.3 Market by Region
5.3.1 Current Performance (2018-2023)
5.3.2 Market Forecast (2024-2032)
5.4 Market by Indication
5.4.1 Autoimmune Diseases
5.4.2 Oncology
5.4.3 Metabolic Disorders
5.4.4 Others
5.5 Market by Class
5.5.1 Recombinant Proteins
5.5.1.1 Current Performance (2018-2023)
5.5.1.2 Market Forecast (2024-2032)
5.5.2 Monoclonal Antibodies
5.5.2.1 Current Performance (2018-2023)
5.5.2.2 Market Forecast (2024-2032)
5.5.3 Purified Proteins
5.5.3.1 Current Performance (2018-2023)
5.5.3.2 Market Forecast (2024-2032)
5.6 Competitive Landscape
5.6.1 Top Biopharmaceutical Players
5.6.2 Top Biopharmaceutical Drugs
5.7 Value Chain Analysis
5.8 Porter’s Five Forces Analysis
5.8.1 Overview
5.8.2 Bargaining Power of Buyers
5.8.3 Bargaining Power of Suppliers
5.8.4 Degree of Rivalry
5.8.5 Threat of New Entrants
5.8.6 Threat of Substitutes
6 North America
6.1 United States
6.1.1 Market Performance (2018-2023)
6.1.2 Market by Class
6.1.2.1 Recombinant Proteins
6.1.2.2 Monoclonal Antibodies
6.1.2.3 Purified Proteins
6.1.3 Top Players
6.1.4 Market Forecast (2024-2032)
6.2 Canada
6.2.1 Market Performance (2018-2023)
6.2.2 Market by Class
6.2.2.1 Recombinant Proteins
6.2.2.2 Monoclonal Antibodies
6.2.2.3 Purified Proteins
6.2.3 Top Players
6.2.4 Market Forecast (2024-2032)
7 Latin America
7.1 Mexico
7.1.1 Market Performance (2018-2023)
7.1.2 Market by Class
7.1.2.1 Recombinant Proteins
7.1.2.2 Monoclonal Antibodies
7.1.2.3 Purified Proteins
7.1.3 Top Players
7.1.4 Market Forecast (2024-2032)
7.2 Brazil
7.2.1 Market Performance (2018-2023)
7.2.2 Market by Class
7.2.2.1 Recombinant Proteins
7.2.2.2 Monoclonal Antibodies
7.2.2.3 Purified Proteins
7.2.3 Top Players
7.2.4 Market Forecast (2024-2032)
7.3 Argentina
7.3.1 Market Performance (2018-2023)
7.3.2 Market by Class
7.3.2.1 Recombinant Proteins
7.3.2.2 Monoclonal Antibodies
7.3.2.3 Purified Proteins
7.3.3 Top Players
7.3.4 Market Forecast (2024-2032)
8 Europe
8.1 Germany
8.1.1 Market Performance (2018-2023)
8.1.2 Market by Class
8.1.2.1 Recombinant Proteins
8.1.2.2 Monoclonal Antibodies
8.1.2.3 Purified Proteins
8.1.3 Top Players
8.1.4 Market Forecast (2024-2032)
8.2 France
8.2.1 Market Performance (2018-2023)
8.2.2 Market by Class
8.2.2.1 Recombinant Proteins
8.2.2.2 Monoclonal Antibodies
8.2.2.3 Purified Proteins
8.2.3 Top Players
8.2.4 Market Forecast (2024-2032)
8.3 Italy
8.3.1 Market Performance (2018-2023)
8.3.2 Market by Class
8.3.2.1 Recombinant Proteins
8.3.2.2 Monoclonal Antibodies
8.3.2.3 Purified Proteins
8.3.3 Top Players
8.3.4 Market Forecast (2024-2032)
8.4 Spain
8.4.1 Market Performance (2018-2023)
8.4.2 Market by Class
8.4.2.1 Recombinant Proteins
8.4.2.2 Monoclonal Antibodies
8.4.2.3 Purified Proteins
8.4.3 Top Players
8.4.4 Market Forecast (2024-2032)
8.5 United Kingdom
8.5.1 Market Performance (2018-2023)
8.5.2 Market by Class
8.5.2.1 Recombinant Proteins
8.5.2.2 Monoclonal Antibodies
8.5.2.3 Purified Proteins
8.5.3 Top Players
8.5.4 Market Forecast (2024-2032)
8.6 Russia
8.6.1 Market Performance (2018-2023)
8.6.2 Market by Class
8.6.2.1 Recombinant Proteins
8.6.2.2 Monoclonal Antibodies
8.6.2.3 Purified Proteins
8.6.3 Top Players
8.6.4 Market Forecast (2024-2032)
8.7 Turkey
8.7.1 Market Performance (2018-2023)
8.7.2 Market by Class
8.7.2.1 Recombinant Proteins
8.7.2.2 Monoclonal Antibodies
8.7.2.3 Purified Proteins
8.7.3 Top Players
8.7.4 Market Forecast (2024-2032)
9 Asia Pacific
9.1 Japan
9.1.1 Market Performance (2018-2023)
9.1.2 Market by Class
9.1.2.1 Recombinant Proteins
9.1.2.2 Monoclonal Antibodies
9.1.2.3 Purified Proteins
9.1.3 Top Players
9.1.4 Market Forecast (2024-2032)
9.2 China
9.2.1 Market Performance (2018-2023)
9.2.2 Market by Class
9.2.2.1 Recombinant Proteins
9.2.2.2 Monoclonal Antibodies
9.2.2.3 Purified Proteins
9.2.3 Top Players
9.2.4 Market Forecast (2024-2032)
9.3 Australia
9.3.1 Market Performance (2018-2023)
9.3.2 Market by Class
9.3.2.1 Recombinant Proteins
9.3.2.2 Monoclonal Antibodies
9.3.2.3 Purified Proteins
9.3.3 Top Players
9.3.4 Market Forecast (2024-2032)
9.4 South Korea
9.4.1 Market Performance (2018-2023)
9.4.1.1 Recombinant Proteins
9.4.1.2 Monoclonal Antibodies
9.4.1.3 Purified Proteins
9.4.2 Top Players
9.4.3 Market Forecast (2024-2032)
9.5 India
9.5.1 Market Performance (2018-2023)
9.5.2 Market by Class
9.5.2.1 Recombinant Proteins
9.5.2.2 Monoclonal Antibodies
9.5.2.3 Purified Proteins
9.5.3 Top Players
9.5.4 Market Forecast (2024-2032)
9.6 Indonesia
9.6.1 Market Performance (2018-2023)
9.6.2 Market by Class
9.6.2.1 Recombinant Proteins
9.6.2.2 Monoclonal Antibodies
9.6.2.3 Purified Proteins
9.6.3 Top Players
9.6.4 Market Forecast (2024-2032)
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Competitive Landscape
11.1 Market Structure
11.2 Key Players
11.3 Profiles of Key Players
11.3.1 AbbVie Inc.
11.3.2 Amgen Inc
11.3.3 Biogen Inc.
11.3.4 Eli Lilly and Company
11.3.5 F. Hoffmann-La Roche AG
11.3.6 Johnson & Johnson
11.3.7 Merck & Co. Inc.
11.3.8 Novo Nordisk A/S
11.3.9 Pfizer Inc.
11.3.10 Sanofi S.A
List of Figures
Figure 1: Global: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 2: Complexity of Biopharmaceuticals
Figure 3: Sources of Biopharmaceuticals
Figure 4: Global: Biopharmaceutical Market: Value Trends (in Billion US$), 2018-2023
Figure 5: Global: Biopharmaceutical Market Forecast: Value Trends (in Billion US$), 2024-2032
Figure 6: Global: Biopharmaceutical Market: Sales Share by Country (in %), 2023
Figure 7: Global: Biopharmaceutical Market Forecast: Sales Share by Country (in %), 2032
Figure 8: Global: Biopharmaceutical Market: Sales Share by Indication (in %), 2023
Figure 9: Global: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 10: Global: Biopharmaceutical Market Forecast: Sales by Class (in Million US$), 2024-2032
Figure 11: Global: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 12: Global: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 13: Global: Recombinant Proteins Market Forecast (in Million US$), 2024-2032
Figure 14: Global: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 15: Global: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 16: Global: Monoclonal Antibodies Market Forecast (in Million US$), 2024-2032
Figure 17: Global: Purified Proteins Market (in Million US$), 2018-2023
Figure 18: Global: Purified Proteins Market: Sales Share by Class (in %), 2023
Figure 19: Global: Purified Proteins Market Forecast (in Million US$), 2024-2032
Figure 20: Global: Biopharmaceutical Market: Sales Share of Top Biopharmaceuticals (in %)
Figure 21: Global: Biopharmaceutical Industry: Value Chain Analysis
Figure 22: Global: Biopharmaceutical Industry: Porter’s Five Forces Analysis
Figure 23: United States: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 24: United States: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 25: United States: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 26: United States: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 27: United States: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 28: United States: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 29: United States: Purified Proteins Market (in Million US$), 2018-2023
Figure 30: United States: Purified Proteins Market: Sales Share by Class (in %), 2023
Figure 31: United States: Biopharmaceutical Market: Sales Share of Top Players (in %), 2023
Figure 32: United States: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 33: United States: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 34: Canada: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 35: Canada: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 36: Canada: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 37: Canada: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 38: Canada: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 39: Canada: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 40: Canada: Biopharmaceutical Market: Sales Share of Top Players (in %), 2023
Figure 41: Canada: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 42: Canada: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 43: Mexico: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 44: Mexico: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 45: Mexico: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 46: Mexico: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 47: Mexico: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 48: Mexico: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 49: Mexico: Purified Proteins Market (in ‘000 US$), 2018-2023
Figure 50: Mexico: Biopharmaceutical Market: Sales Share of Top Players (in %), 2023
Figure 51: Mexico: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 52: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 53: Brazil: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 54: Brazil: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 55: Brazil: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 56: Brazil: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 57: Brazil: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 58: Brazil: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 59: Brazil: Purified Proteins Market (in Million US$), 2018-2023
Figure 60: Brazil: Biopharmaceutical Market: Sales Share of Top Players (in %), 2023
Figure 61: Brazil: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 62: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 63: Argentina: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 64: Argentina: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 65: Argentina: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 66: Argentina: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 67: Argentina: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 68: Argentina: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 69: Argentina: Purified Proteins Market (in Million US$), 2018-2023
Figure 70: Argentina: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 71: Argentina: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 72: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 73: Germany: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 74: Germany: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 75: Germany: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 76: Germany: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 77: Germany: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 78: Germany: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 79: Germany: Purified Proteins Market (in Million US$), 2018-2023
Figure 80: Germany: Purified Proteins Market: Sales Share by Class (in %), 2023
Figure 81: Germany: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 82: Germany: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 83: Germany: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 84: France: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 85: France: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 86: France: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 87: France: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 88: France: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 89: France: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 90: France: Purified Proteins Market (in Million US$), 2018-2023
Figure 91: France: Biopharmaceutical Market: Sales Share of Top Players (in %), 2023
Figure 92: France: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 93: France: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 94: Italy: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 95: Italy: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 96: Italy: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 97: Italy: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 98: Italy: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 99: Italy: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 100: Italy: Purified Proteins Market (in Million US$), 2018-2023
Figure 101: Italy: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 102: Italy: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 103: Italy: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 104: Spain: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 105: Spain: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 106: Spain: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 107: Spain: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 108: Spain: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 109: Spain: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 110: Spain: Purified Proteins Market (in Million US$), 2018-2023
Figure 111: Spain: Purified Proteins Market: Sales Share by Class (in %), 2023
Figure 112: Spain: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 113: Spain: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 114: Spain: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 115: UK: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 116: UK: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 117: UK: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 118: UK: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 119: UK: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 120: UK: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 121: UK: Purified Proteins Market (in Million US$), 2018-2023
Figure 122: UK: Purified Proteins Market: Sales Share by Class (in %), 2023
Figure 123: UK: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 124: UK: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 125: UK: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 126: Russia: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 127: Russia: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 128: Russia: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 129: Russia: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 130: Russia: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 131: Russia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 132: Russia: Purified Proteins Market: (in Million US$), 2018-2023
Figure 133: Russia: Purified Proteins Market: Sales Share by Class (in %), 2023
Figure 134: Russia: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 135: Russia: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 136: Russia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 137: Turkey: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 138: Turkey: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 139: Turkey: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 140: Turkey: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 141: Turkey: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 142: Turkey: Purified Proteins Market (in Million US$), 2018-2023
Figure 143: Turkey: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 144: Turkey: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 145: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 146: Japan: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 147: Japan: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 148: Japan: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 149: Japan: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 150: Japan: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 151: Japan: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 152: Japan: Purified Proteins Market (in Million US$), 2018-2023
Figure 153: Japan: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 154: Japan: Biopharmaceutical Market Forecast: Value trend (in Million US$), 2024-2032
Figure 155: Japan: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 156: China: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 157: China: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 158: China: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 159: China: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 160: China: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 161: China: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 162: China: Purified Proteins Market: (in Million US$), 2018-2023
Figure 163: China: Purified Proteins Market: Sales Share by Class (in %), 2023
Figure 164: China: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 165: China: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 166: China: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 167: Australia: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 168: Australia: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 169: Australia: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 170: Australia: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 171: Australia: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 172: Australia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 173: Australia: Purified Proteins Market (in Million US$), 2018-2023
Figure 174: Australia: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 175: Australia: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 176: Australia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 177: South Korea: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 178: South Korea: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 179: South Korea: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 180: South Korea: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 181: South Korea: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 182: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2023
Figure 183: South Korea: Purified Proteins Market (in Million US$), 2018-2023
Figure 184: South Korea: Purified Proteins Market: Sales Share by Class (in %), 2023
Figure 185: South Korea: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 186: South Korea: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 187: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 188: India: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 189: India: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 190: India: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 191: India: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 192: India: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 193: India: Purified Proteins Market (in Million US$), 2018-2023
Figure 194: India: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 195: India: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 196: India: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 197: Indonesia: Biopharmaceutical Market (in Million US$), 2018-2023
Figure 198: Indonesia: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
Figure 199: Indonesia: Recombinant Proteins Market (in Million US$), 2018-2023
Figure 200: Indonesia: Recombinant Proteins Market: Sales Share by Class (in %), 2023
Figure 201: Indonesia: Monoclonal Antibodies Market (in Million US$), 2018-2023
Figure 202: Indonesia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
Figure 203: Indonesia: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 204: Indonesia: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
Figure 205: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
Figure 206: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2001 & 2022
Figure 207: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products
Figure 208: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used
Figure 209: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %)
Figure 210: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs (in US$)
Figure 211: Emerging Biopharmaceutical Market Forecast (in Million US$), 2023 & 2032
Figure 212: Developed Biopharmaceutical Market Forecast (in Million US$), 2023 & 2032
Figure 213: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in Numbers), 2002-2022
Figure 214: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs (in Million US$)
Figure 215: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months)
List of Tables
Table 1: Global: Biopharmaceutical Market: Definition & Segmentation
Table 2: Global: Biopharmaceutical Market: SWOT Analysis
Table 3: Global: Biopharmaceutical Market Forecast: Sales by Region (in Million US$), 2023 & 2032
Table 4: Differences Between Small Molecule Drugs & Biopharmaceuticals
Table 5: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs
Table 6: Global: Biopharmaceutical Market: Sales by Country (in Million US$), 2018-2023
Table 7: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million US$), 2024-2032
Table 8: Global: Biopharmaceutical Market: Sales by Indication (in Billion US$), 2023
Table 9: Mode of Administration of Popular Biotech Drugs